NCT03362047View on ClinicalTrials.gov

(RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

July 3, 2024

Study Completion Date

August 14, 2024

Conditions
Pulmonary Arterial Hypertension (PAH)
Interventions
DRUG

Riciguat Group

Patients will be administered 12 weeks Riciguat

DRUG

Macitentan Group

Patients will be administered 12 weeks Macitentan

Trial Locations (3)

35392

Abteilung Pneumologie und Intensivmedizin der Medizinischen Klinik II, Uniklinik Gießen und Marburg Standort Gießen, Giessen

80639

Krankenhaus Neuwittelsbach, Innere Medizin II, München

D-50973

Klinik III für Innere Medizin Herzzentrum der Universität zu Köln, Cologne

All Listed Sponsors
collaborator

Philipps University Marburg

OTHER

lead

University of Giessen

OTHER

NCT03362047 - (RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment) | Biotech Hunter | Biotech Hunter